Indian biopharmaceutical company inaugurated its first manufacturing facility in Cranbury, New Jersey, on September 10, 2025. New Jersey Governor Phil Murphy attended the ceremony alongside Biocon Chairperson Kiran Mazumdar-Shaw and industry representatives.
The facility, operated by Biocon’s wholly-owned subsidiary Biocon Generics Inc., produces oral solid dosage medications with an annual capacity of 2 billion tablets. The company acquired the plant from Eywa Pharma Inc. in 2023 and invested over $30 million in upgrades to create the state-of-the-art facility.
Several products have already begun commercial production at the site, with additional medications in development. The facility has received US FDA approval for formulations manufacturing, marking a significant milestone for the Bangalore-based company’s global expansion strategy.
The investment aims to strengthen Biocon’s supply chain resilience and accelerate market access for its generic medications across the United States. The proximity to US healthcare providers and partners is expected to improve delivery efficiency for the company’s vertically integrated medicines portfolio.
Biocon, publicly listed since 2004, specialises in biologics, biosimilars and generic formulations for chronic conditions including diabetes, cancer and autoimmune diseases. The company operates manufacturing facilities in India and serves markets in the US, Europe and other global regions. The New Jersey facility represents its first manufacturing presence on US soil.
The shares of Biocon Limited were trading flat at ₹363.85 on the today at 11.50 am.